Thursday, May 01, 2025 2:03:09 PM
You keep throwing punches at MK like you’re exposing some grand failure, but all you’re really doing is making noise that doesn’t hold up under scrutiny. The problem with your narrative isn’t that it’s critical—it’s that it’s lazy.
You rant about Y-90 shelf life like Vivos is overnighting finished doses across oceans, when in reality you have no access to the protocols, the QA process, or how the components are handled before administration. But that’s the play, isn’t it? Toss out assumptions, wrap them in outrage, and hope no one notices the lack of substance.
Same with the rabbit study. You say it was botched, then backpedal into timing complaints and speculation about why the IDE was pulled—as if that somehow proves your case. You call it a failure, but the FDA hasn’t even ruled on the revised data yet. So either you're claiming to know more than the FDA, or you're just hoping your audience doesn’t.
And let’s talk about your constant fallback: “MK is a moron.” It’s tired. It’s weak. If he were half as incompetent as you claim, there wouldn’t be an India trial, there wouldn’t be FDA engagement, and there wouldn’t be a product that’s even remotely this close to an IDE refile. But here we are.
You’re not pointing out flaws—you’re building a narrative that serves your agenda. You want MK to fail so badly you’re willing to pretend every strategic delay is a collapse, and every adaptation is a blunder. But the market isn’t stupid forever. Eventually, people start looking past the smoke, and when they do, your story won’t hold.
$RDGL
You rant about Y-90 shelf life like Vivos is overnighting finished doses across oceans, when in reality you have no access to the protocols, the QA process, or how the components are handled before administration. But that’s the play, isn’t it? Toss out assumptions, wrap them in outrage, and hope no one notices the lack of substance.
Same with the rabbit study. You say it was botched, then backpedal into timing complaints and speculation about why the IDE was pulled—as if that somehow proves your case. You call it a failure, but the FDA hasn’t even ruled on the revised data yet. So either you're claiming to know more than the FDA, or you're just hoping your audience doesn’t.
And let’s talk about your constant fallback: “MK is a moron.” It’s tired. It’s weak. If he were half as incompetent as you claim, there wouldn’t be an India trial, there wouldn’t be FDA engagement, and there wouldn’t be a product that’s even remotely this close to an IDE refile. But here we are.
You’re not pointing out flaws—you’re building a narrative that serves your agenda. You want MK to fail so badly you’re willing to pretend every strategic delay is a collapse, and every adaptation is a blunder. But the market isn’t stupid forever. Eventually, people start looking past the smoke, and when they do, your story won’t hold.
$RDGL
Know what you own, and know why you own it.
Recent RDGL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:45:22 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
